2017 Call for Papers and Posters - Now Closed
The system will close at 11:59 am PST on January 10, 2017, and additional submissions will not be accepted. The deadline will not be extended.
Submitters will be notified in February, 2017, regarding selection of their abstract.
Pediatric Blood and Marrow Transplant Consortium (PBMTC) will also be holding an educational program in conjunction with the ASPHO Annual Meeting on Wednesday, April 26, 2017. PBMTCs posters will be collected through their own call found on their website. Abstracts can be submitted to one meeting or the other — not to both. The abstracts for both organizations will be published online in Pediatric Blood & Cancer.
The goal of the ASPHO Program Committee is to solicit the very best, original, basic, clinical, and social science abstracts that relate to the field of pediatric hematology and oncology.
It is understood that any individual abstract may be part of an on-going project. Paper/Poster abstracts previously presented or published in whole or in part may be submitted to the ASPHO. However, abstracts should be updated or modified in some way.
Authors should please note: ASPHO has always allowed previously presented work (i.e., a platform talk presented at the ASH meeting in December of the year prior to the ASPHO spring meeting) to be presented at the ASPHO meetings. Many societies/meetings do not allow such double presentations, so authors are encouraged to verify the rules for any meeting that may occur after the ASPHO annual meeting. Material that has been or is expected to be published in manuscript form before the dates of the ASPHO meeting is not acceptable for presentation in either poster or platform formats.
Case Reports are acceptable as poster abstracts, they will be graded separately from the other themes, and authors should be aware of the following:
- If it is a single case report, the uniqueness of the case (i.e., has this ever been described before?), and the relevance of the case, the treatment used, or the biology involved must be clearly discussed. The quality of the discussion and the uniqueness of the case are generally the primary factors in whether these abstracts are deemed acceptable for (usually poster) presentation.
- In general, single case reports are discouraged, and authors are instead encouraged to see if they can put together at least a small series of similar cases.
- The committee is aware that this may be the only way for a student, fellow, or junior faculty to submit an abstract and come to the meeting, so the presenting author on such abstracts should usually be an author who fits in one of these categories.
- NEW THIS YEAR - Case reports will not be published in the journal.
Important Information about Submission and Issues Related to Copyright
The submitter will be asked to sign an Abstract Submission Agreement which confirms that they agree to grant ASPHO unrestricted, irrevocable permission to publish the abstract in printed materials, in a searchable data base, at www.aspho.org, and PDF file. The submitter retains the abstract's copyright, and anyone wishing to use the abstract after the ASPHO meeting will be instructed to contact the submitter for permission.
All communication will go to the submitter.
Abstracts are limited to 400 words. New this year: Tables and charts will not be accepted.
All submitters, including those who submit case reports, must include the following components in the body of the abstract:
- Submitters must indicate the institution, city, state and country where the research was conducted.
It is essential that each submitter select a theme (topic) for the abstract being submitted. This information is used for the appropriate grouping of papers and posters at the annual meeting as well as for publication in ASPHO's online journal, Pediatric Blood & Cancer, and on the ASPHO website.
- Hemostasis, Thrombosis, and Vascular Biology
- Red Cells
- Leukemia/Lymphoma/Histiocyte Disorders
- Solid Tumors
- Bone Marrow Transplant
- Case Reports
- Outcomes Research
- Outcomes Research is researh that describes the end result of health care practices and interventions. Examples include studies related to cost effectiveness, health status, disease burden, late effects of treatment, and quality of life.
- Quality Improvement/Patient Safety
The quality improvement abstracts are based on improvement of health and health care. The abstracts can be related to patient safety, processes to improve outcomes such as time to antibiotics and influenza initiatives but the abstracts need to be based on clear evidence. Abstracts should mention key terms such as Global and Smart aims, Key Drivers, PDSA ramps, and run charts. Quality of life and survivorship abstracts should be submitted in the appropriate disease category.
Submitters should also indicate if:
- they will be applying for the ASPHO Young Investigator Award or the ASPHO Early Career Travel Stipend Award
- their preferred presentation format: oral, poster, or both.
- the abstract was accepted at any other national meeting(s). If the abstract was previously presented:
- indicate format: poster or platform;
- indicate at what meeting the abstract was presented at;
- indicate whether or not the abstract has been modified and why you feel a second presentation is important.
If you must cite a reference, please do so at the end of your abstract using the following format: author name, publication name, and year of publication, e.g., (Smith, Ped Blood & Cancer, 2016).
All accepted abstracts will be published on the ASPHO website and in the Pediatric Blood & Cancer journal (online format) as submitted. Please check your submission carefully before clicking the "Submit" button in the submission system. ASPHO will not allow any changes to the abstract once the system closes on January 10, 2017. Abstracts will be presented in the journal (online format) and on the ASPHO website as they appear at the time of submission.
Meeting Registration Guidelines for Presenters
Paper and poster abstracts will be presented during concurrent session time blocks throughout the annual meeting.
Papers and posters will be presented on Thursday, April 27, Friday, April 28, or Saturday, April 29. Presentation times will be assigned at the time the abstract is accepted; authors cannot request a specific presentation date/time. Prior to submission of a paper or poster, at least one author must agree to attend the ASPHO meeting and to participate as the paper or poster presenter. ASPHO will not waive the registration fee for presenters. Presenters are responsible for all personal expenses (e.g., travel, hotel) and for conference registration fees. Presenters are encouraged to register for the meeting and to reserve hotel accommodations as early as possible to ensure that space is available.
Policy on Commercial Support
Presentations must avoid commercialism and should conform to accreditation standards for commercial support. Presentations that constitute promotion and advertising will not be accepted, including pervasive or inappropriate use of logos. No company product information may be displayed or disseminated in conjunction with the presentation.
If the author(s) received any funding for this research, a clear acknowledgment of support should be included at the end of the abstract, e.g., Supported by a grant from ABC Pharmaceuticals.
Paper and poster submissions will be reviewed and rated by members of the Program Committee who have expertise in the research or clinical area to which the submission belongs. Each submission will be reviewed for its scientific or clinical importance, ethical practice, and study design.
An alphabetical list of the submitters' names will be posted on the ASPHO website, in February, 2017. This will be a submitter's first opportunity to learn whether an abstract was accepted or rejected for presentation, and in what format. All communications will be directed to the submitter. If the submitter and presenting authors are different, communication will continue through the submitter. It is the responsibility of the submitter to communicate with the presenting author. The presenting author must be a coauthor on the abstract.
Submitters of paper abstracts will be notified in February of 2017 by e-mail of their abstract's acceptance or rejection. All authors on submissions considered for paper presentation will be required to complete a disclosure form; details will be included with the notification letter.
Submitters of poster abstracts will be notified in February of 2017 by e-mail of their abstract's acceptance or rejection.
Late Breaking Abstracts
ASPHO does not allow late breaking abstracts. All submissions must be received by the January 10, 2017, deadline.